This is a proof of concept, randomized, open label, 2-arm study of OPRX-106 in subjects with active mild to moderate ulcerative colitis. Eligible subjects will be enrolled and randomized to receive 2 mg or 8 mg of OPRX-106 administered orally, once daily for 8 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Oral delivery, once daily.
Soroka University Hospital
Beersheba, Israel
RECRUITINGRambam Health Care Campus
Haifa, Israel
RECRUITINGHadassah Medical Center
Jerusalem, Israel
Adverse events following daily administration of OPRX 106
Adverse events from subject reporting or other assessments
Time frame: 70 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Shaare-Zedek Medical Center
Jerusalem, Israel
NOT_YET_RECRUITINGGalilee Medical Center
Nahariya, Israel
NOT_YET_RECRUITINGAssaf-Harofeh Medical Center
Rishon LeZiyyon, Israel
NOT_YET_RECRUITINGTel-Aviv Sourasky Medical Center
Tel Aviv, Israel
RECRUITING